David C Rettew1, Jeanne Greenblatt2, Jody Kamon3, Diane Neal4, Valerie Harder3, Richard Wasserman3, Patricia Berry3, Charles D MacLean5, Nancy Hogue6, William McMains7. 1. The Vermont Center for Children, Youth, and Families, Department of Psychiatry, University of Vermont, Burlington, Vermont; Vermont Child Health Improvement Program, Department of Pediatrics, and david.rettew@med.uvm.edu. 2. The Vermont Center for Children, Youth, and Families, Department of Psychiatry, University of Vermont, Burlington, Vermont; Vermont Child Health Improvement Program, Department of Pediatrics, and. 3. Vermont Child Health Improvement Program, Department of Pediatrics, and. 4. Catamaran, Schaumburg, Illinois; 5. Department of Medicine, University of Vermont College of Medicine, Burlington, Vermont; 6. Department of Vermont Health Access, Williston, Vermont; and. 7. Vermont Department of Mental Health, Williston, Vermont.
Abstract
BACKGROUND: Although the increase in treatment of children and adolescents with antipsychotic medications has been well documented, much less is known about the factors related to the use of these agents and how closely the treatment follows best practice recommendations. METHODS: Prescribers of each antipsychotic medication prescription issued for a Medicaid-insured child in Vermont aged <18 years were sent a prior authorization survey that assessed several domains including the clinical indication, other treatments, metabolic monitoring, prescriber specialty, and prescription origin. These variables were combined to categorize prescriptions as following indications approved by the US Food and Drug Administration (FDA) and best practice guidelines. RESULTS: The response rate of the survey was 80%, with 677 surveys from 147 prescribers available for analysis; more than one-half of the respondents were primary care clinicians. Overall, the clinical indication for an antipsychotic prescription followed best practice guidelines 91.7% of the time, with overall best practice guidelines followed at a rate of 50.1%. An FDA indication was followed in 27.2% of cases. Psychiatrists were significantly more likely to follow best practice guidelines than nonpsychiatrists. Antipsychotic medications were typically used only after other pharmacologic and nonpharmacologic treatments were ineffective, although previous treatment with cognitive-behavioral therapy was uncommon (15.5%). Metabolic monitoring that included serial laboratory tests was reported in 57.2% of cases. CONCLUSIONS: Current prescribing patterns of antipsychotic medications for children and adolescents follow best practice guidelines approximately one-half of the time, with nonadherence often related to lack of metabolic monitoring.
BACKGROUND: Although the increase in treatment of children and adolescents with antipsychotic medications has been well documented, much less is known about the factors related to the use of these agents and how closely the treatment follows best practice recommendations. METHODS: Prescribers of each antipsychotic medication prescription issued for a Medicaid-insured child in Vermont aged <18 years were sent a prior authorization survey that assessed several domains including the clinical indication, other treatments, metabolic monitoring, prescriber specialty, and prescription origin. These variables were combined to categorize prescriptions as following indications approved by the US Food and Drug Administration (FDA) and best practice guidelines. RESULTS: The response rate of the survey was 80%, with 677 surveys from 147 prescribers available for analysis; more than one-half of the respondents were primary care clinicians. Overall, the clinical indication for an antipsychotic prescription followed best practice guidelines 91.7% of the time, with overall best practice guidelines followed at a rate of 50.1%. An FDA indication was followed in 27.2% of cases. Psychiatrists were significantly more likely to follow best practice guidelines than nonpsychiatrists. Antipsychotic medications were typically used only after other pharmacologic and nonpharmacologic treatments were ineffective, although previous treatment with cognitive-behavioral therapy was uncommon (15.5%). Metabolic monitoring that included serial laboratory tests was reported in 57.2% of cases. CONCLUSIONS: Current prescribing patterns of antipsychotic medications for children and adolescents follow best practice guidelines approximately one-half of the time, with nonadherence often related to lack of metabolic monitoring.
Authors: Haiden A Huskamp; Marcela Horvitz-Lennon; Ernst R Berndt; Sharon-Lise T Normand; Julie M Donohue Journal: Psychiatr Serv Date: 2016-07-15 Impact factor: 3.084
Authors: Christina D Kang-Yi; Jill Locke; Melanie Pellecchia; Steve C Marcus; Trevor Hadley; David S Mansell Journal: School Ment Health Date: 2015-12-28
Authors: Rebecca P Barclay; Robert B Penfold; Donna Sullivan; Lauren Boydston; Julia Wignall; Robert J Hilt Journal: Health Serv Res Date: 2017-04 Impact factor: 3.402
Authors: Mariken Dinnissen; Andrea Dietrich; Judith H van der Molen; Anne M Verhallen; Ynske Buiteveld; Suzanne Jongejan; Pieter W Troost; Jan K Buitelaar; Barbara J van den Hoofdakker; Pieter J Hoekstra Journal: J Clin Psychopharmacol Date: 2021 Jan/Feb 01 Impact factor: 3.118